Abstract

In the unblinded, randomized Abciximab and Carbostent Evaluation trial, high-risk patients with ST-segment-elevation acute MI underwent primary

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call